Intarcia and Numab link up to develop once-yearly therapies in diabetes and other indications

Privately-held US biotech firm Intarcia Therapeutics and Swiss firm Numab have announced a strategic collaboration focused on the development of once- or twice-yearly mono-specific and multi-specific antibodies addressing diabetes, obesity and autoimmune indications.

Under the terms of the collaboration, Numab is eligible to receive undisclosed upfront and contingent milestone payments, as well as tiered single to low double-digit royalties on any sales resulting from collaborative efforts. Intarcia has the option to extend the collaboration beyond the initial assets and targets as well as the opportunity to purchase a strategic interest in Numab AG at a pre-defined time point. Intarcia will be responsible for the development, manufacturing and commercialization of all products stemming from the collaboration.

Complements Intarcia’s disruptive platform technologies